Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Boron Neutron Capture Therapy (BNCT) for Patients With Unresectable Angiosarcoma, by Using CICS-1 and SPM-011

NCT05601232 is registered in ClinicalTrials.gov with Stella Pharma Corporation as lead sponsor.

NCT NCT05601232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Boron Neutron Capture Therapy (BNCT) for Patients With Unresectable Angiosarcoma, by Using CICS-1 and SPM-011
Lead sponsor
Stella Pharma Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2022
Completion date
August 31, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable angiosarcoma